OR WAIT 15 SECS
Polish researchers writing in the journal Reumatologia outline algorithms used to assess cardiovascular disease risk in rheumatoid arthritis, PsA and AS patients.
Polish researchers writing in the journal Reumatologiasay there is a need for a new algorithm to assess cardiovascular disease in rheumatoid arthritis patients.
But this is easier said than done, they write. Rhematologists, cardiologists and general practitioners need to agree on screening methods and perhaps on a rheumatoid arthritis specific calculator.
Cardiovascular disease (CVD) in rheumatoid arthritis (RA) patients is complex. A clear link exists between inflammation, lipid metabolism and cardiovascular disease.
What is poorly understood is the connection between treatments for RA and CVD, the authors write. Some studies, including QUEST-RA, show that methotrexate and sulfasalazine are associated with a reduced prevalence of cardiovascular events. And, the debate on whether disease-modifying anti-rheumatic drugs (DMARDs) and biologics contribute to or lessen CVD risk, remains controversial, wrote Krzysztof Bonek and Piotr Gluszko, of the National Institute of Geriatrics, Rheumatology and Rehabilitation in Poland. The article appears in the July 18 issue of the journal.
“It is necessary to consider the new guidelines presented in the USA in 2013 by the American College of Cardiology/American Heart Association (ACC/AHA). Their CV risk estimation method is based on a new Poled Cohort Equation formula,” the authors wrote.
The authors of the study highlight and evaluate some of the most commonly used CVD-risk calculators.
CVD Risk Calculators
The List: CVD Risk Assessment
The European League Against Rheumatism (EULAR) recently highlighted key factors physicians should consider in evaluating patients with rheumatoid arthritis, ankylosing spondylitis (AS) and psoriatic arthritis (PsA) for CVD risk. “They also pointed out the need to create a new RA-focused cardiovascular risk calculator, stating that the current methods of cardiovascular risk assessment are maladjusted,” the authors wrote.
The EULAR group stated that:
Bonek K, GÅuszko P. “Cardiovascular risk assessment in rheumatoid arthritis – controversies and the new approach.” Reumatologia/Rheumatology r. 2016;3:128-135. DOI:10.5114/reum.2016.61214.